广东品晟医药科技

Pinsheng Pharma is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on the field of synthetic lethality and DNA damage response (DDR) to address unmet medical needs in oncology. Its lead candidate, PS-001, is a potent and selective USP1 inhibitor currently undergoing clinical evaluation for the treatment of advanced solid tumors, particularly those with homologous recombination deficiency. Pinsheng Pharma leverages its proprietary drug discovery platform to build a robust pipeline of precision medicines targeting various cancers and metabolic disorders. The company is led by a team of industry veterans with extensive experience in global drug development.